Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate Total plaque, gingivitis claims evolution detailed in FDA review documents.

This article was originally published in The Tan Sheet

Executive Summary

COLGATE TOTAL CLAIMS EVOLUTION DETAILED IN FDA REVIEW DOCUMENTS recently made available by the agency for the .3% triclosan/.24% sodium fluoride OTC toothpaste. Colgate Total was approved July 11, 1997 as the first OTC dentifrice allowed to claim efficacy in the prevention of gingivitis, in addition to plaque, tartar, cavities and bad breath ("The Tan Sheet" July 21, 1997, p. 1). The company submitted NDA 20-231 to the agency Dec. 29, 1992, and it was reviewed by FDA's Division of Dermatologic & Dental Drug Products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel